Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ovid Therapeutics Inc
(NQ:
OVID
)
1.210
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ovid Therapeutics Inc
< Previous
1
2
Next >
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
August 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
August 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
August 01, 2024
From
The Schall Law Firm
Via
Business Wire
Ovid Therapeutics to Present at Upcoming August Investor Conferences
July 30, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
July 23, 2024
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
July 10, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
July 01, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
June 17, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
May 14, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
March 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
December 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 03, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 30, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 04, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 28, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Added to Russell 3000® Index
June 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 05, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
May 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
April 27, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.